Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Expands By 21.8%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totaling 8,751 shares, a growth of 21.8% from the March 15th total of 7,185 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 27,194 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma as of its most recent SEC filing. 11.77% of the stock is owned by hedge funds and other institutional investors.

Matinas Biopharma Price Performance

Matinas Biopharma stock opened at $0.50 on Friday. Matinas Biopharma has a one year low of $0.48 and a one year high of $3.09. The company’s fifty day moving average price is $0.58 and its two-hundred day moving average price is $0.87. The company has a market capitalization of $3.21 million, a price-to-earnings ratio of -0.25 and a beta of 1.39.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.26) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.